To identify promising therapeutic candidates for AD, we conducted MD simulations to evaluate the binding interactions between seven drug candidates with predicted BBB permeability (Vorapaxar, Bictegravir, Tonaftate, Fluspirilene, Lisuride, Lasmiditan, and Olaparib) and five DER protei targets (ZEB2, APP, PAX6, ETV6, and ST18). Here, PAX6 is linked to Alzheimer disease.